PUNE, India, 16 October 2026 — NeoGraph Analytics has published a public methodology and forty new market reports built to it, each with its headline figure tested against a countable public register before publication.
The methodology commits to four things a reader can hold us to. Published estimates are collected and compared rather than averaged, with each publisher's stated scope recorded next to its number. Every headline is divided through by something countable. Sections appear only where evidence exists — which means vendor market shares, undisclosed regional splits and unsourced segment percentages are routinely absent on purpose. And each report is checked mechanically before it goes out: the stated growth rate has to reconnect the base-year value to the forecast value across the stated period, the plotted series has to begin at the base year on exactly the base-year figure, and every chart has to carry a source.
What the grounding found
Applied across forty markets, the test did not quietly confirm the literature. In several cases it contradicted it outright, and the contradiction is the report's finding:
- CAR-T cell therapy. Five approved products from three companies reported $5.53 billion of FY2025 revenue in audited filings — more than any published base-year size for the same market, including one published for 2025 itself. Report
- GLP-1 receptor agonists. Two companies disclose $71.94 billion of GLP-1 revenue; three of five published market sizes are below that, and one is smaller than a single quarter of one brand. Report
- Plasma fractionation. Three suppliers' disclosed revenue is 80.9% of one published global market; adding a single immunoglobulin line from a fourth reaches 96.4% of it. Report
- Proteomics. One publisher's instruments line alone exceeds the entire analytical-instruments segment revenue of the largest supplier in the field, across all applications. Report
- Orthopaedic implants. Five companies' disclosed segment revenue sums to 120.8% of one publisher's entire global market. Report
- Liquid biopsy. The highest published forecast implies roughly 43 million tests a year against about 20 million annual cancer cases worldwide — an unstated assumption of population screening rather than therapy selection. Report
Where the estimates disagree, and why
Across the forty markets, base-year estimates for the same market and year spread by as much as 24 times, while published growth rates for those same markets frequently spread by less than 1.4 times. The pattern is consistent: forecasters broadly agree about how fast a market grows and disagree about what the market is.
Two instances are worth stating plainly, because they cannot be explained as independent houses reaching different conclusions. In health data interoperability, one publisher's own catalogue carries figures roughly 33 times apart for the same horizon. In sterile injectables, a single publisher holds both ends of a 13.6x spread. In spatial biology, one house's narrow-scope figure exceeds its own wider-scope figure by 5.4 times.
NeoGraph's position is that a report whose headline is a single number is reporting the analyst's scope decision, not a finding about the market. Its reports therefore lead with the range, the scope difference that explains it, and the arithmetic that eliminates part of it.
What is deliberately not published
The methodology also commits NeoGraph to omissions. Vendor market share is almost never publicly disclosed, so competitive sections name the players and describe their position in words rather than attaching percentages — and where the only figures in circulation are a decade old, the reports say so instead of repeating them. Regional and country splits that no source provides are left absent rather than apportioned. Segment lists appear without percentages where only the list is known.
Two of the forty reports are published with no revenue base at all: in phage therapy, no product holds marketing authorisation in the United States, the European Union or the United Kingdom, and the report presents the published figures as option value on an unread Phase 3 rather than as revenue. In psychedelic therapeutics, two approved products that are not psychedelics — an oxybate franchise and esketamine — already account for 113.5% of one publisher's entire market base, which leaves the psychedelics themselves an implied value below zero.
Availability
The methodology is at neographanalytics.com/methodology and is linked from the caption of every chart on the site. The reports are available at neographanalytics.com/reports. Readers who hold a source that conflicts with a published figure are asked to contact the research desk with the figure and the source; corrections are preferred to defences.
About NeoGraph Analytics
NeoGraph Analytics is a healthcare and life-sciences research publication. Its output is market analysis grounded in primary sources — company filings, regulatory registers and public statistics — with the arithmetic shown.
Media contact: Research desk, NeoGraph Analytics.
Figures cited above are reproduced from named company filings and named published estimates; the source list for each, including the figures examined and not published, sits with the report.